Cargando…

Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer

Background: Anlotinib is a small molecular multi-targeting tyrosine kinase inhibitor. Growing evidence indicates that treatment efficacy, and toxicity varies considerably between individuals. Therefore, this study aimed to investigate the relationship between cytochrome P450 (CYP450) gene polymorphi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Tingfei, Han, Gongwei, Cheng, Ziwei, Jiang, Jiemei, Zhang, Li, Xia, Zitong, Wang, Xinmeng, Xia, Quan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257029/ https://www.ncbi.nlm.nih.gov/pubmed/35814206 http://dx.doi.org/10.3389/fphar.2022.918219

Ejemplares similares

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
por: Lee, Fei Yee, et al.
Publicado: (2022)

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
por: Nie, Shanshan, et al.
Publicado: (2022)

Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions
por: Gao, Beibei, et al.
Publicado: (2022)

Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib
por: Li, Shiting, et al.
Publicado: (2023)

Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
por: Liu, Shuaibing, et al.
Publicado: (2017)

CYP2A6 and GABRA2 Gene Polymorphisms are Associated With Dexmedetomidine Drug Response
por: Fang, Chao, et al.
Publicado: (2022)

Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases
por: Chen, Jianqiao, et al.
Publicado: (2022)

CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous System—Results From the ADRED Study
por: Just, Katja S., et al.
Publicado: (2021)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6(∗)10 on Interindividual Variation in a Chinese Population
por: Chen, Rui, et al.
Publicado: (2017)

Comparison of Adverse Reactions Caused by Olaparib for Different Indications
por: Zhou, Yujing, et al.
Publicado: (2022)

The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions
por: Li, Yanping, et al.
Publicado: (2022)

Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis
por: Chen, Weimou, et al.
Publicado: (2021)

Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report
por: Mao, Jiwei, et al.
Publicado: (2023)

The Impact of Plasma Protein Binding Characteristics and Unbound Concentration of Voriconazole on Its Adverse Drug Reactions
por: Yuan, Zi-Qing-Yun, et al.
Publicado: (2020)

Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C9*72-*75 in the Chinese Han population
por: Zhao, Fang-Ling, et al.
Publicado: (2022)

Genetic polymorphisms influencing deferasirox pharmacokinetics, efficacy, and adverse drug reactions: a systematic review and meta-analysis
por: Yampayon, Kittika, et al.
Publicado: (2023)

Adverse Drug Reactions Caused by Antimicrobials Treatment for Ventilator-Associated Pneumonia
por: Shen, Shan, et al.
Publicado: (2022)

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
por: Yang, Qunying, et al.
Publicado: (2021)

Pharmacogenomics and adverse drug reactions in children
por: Rieder, Michael J., et al.
Publicado: (2014)

The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva
por: Jin, Ye, et al.
Publicado: (2022)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine
por: Ye, Zhize, et al.
Publicado: (2022)

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
por: Zhu, Zhongling, et al.
Publicado: (2021)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Jiang, Fenge, et al.
Publicado: (2022)

Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
por: Contreras-Castillo, Stephania, et al.
Publicado: (2021)

Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease
por: Zhou, Xiao-hong, et al.
Publicado: (2020)

Evaluation of Selected CYP51A1 Polymorphisms in View of Interactions with Substrate and Redox Partner
por: Režen, Tadeja, et al.
Publicado: (2017)

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism
por: Gao, Nanyong, et al.
Publicado: (2022)

Characterization of 15 CYP2J2 variants identified in the Chinese Han population on the metabolism of ebastine and terfenadine in vitro
por: Zou, Li-Li, et al.
Publicado: (2023)

Identification and Analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in Cynomolgus Macaques
por: UNO, Yasuhiro, et al.
Publicado: (2014)

Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo
por: Wang, Gangyang, et al.
Publicado: (2022)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Frontiers Production Office,
Publicado: (2022)

Central retinal vein occlusion with cerebral infarction secondary to anlotinib treatment: a case report and literature review
por: Chen, Yingying, et al.
Publicado: (2023)

Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform
por: Kabir, Md, et al.
Publicado: (2022)

Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy
por: Poblete, Daniela, et al.
Publicado: (2021)

Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug
por: Li, Qian, et al.
Publicado: (2021)

Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients
por: Matthaei, Johannes, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rdh48qt4j3mv0in3adeobe28ps